SECURITIES AND EXCHANGE COMMISSION

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________



FORM 8-K


CURRENT REPORT


Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

________________

 


Date of Report (Date of earliest event reported):
May 23, 2006

 

Alpharma Inc.

 

(Exact name of registrant as specified in its charter)

 

Delaware
(State or other jurisdiction of incorporation)

1-8593
(Commission File
Number)

22-2095212
(IRS Employer Identification)

 

One Executive Drive, Fort Lee, New Jersey 07024
(Address of principal executive offices) (Zip Code)

 

Registrant's telephone number, including area code
(201) 947-7774

 
 

Not Applicable

______________________________________________
(Former name or former address, if changed since

last report)

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

On May 23, 2006 the Board of Directors of the Registrant approved an amendment of sections 2.8 and 4.3(c) of the Registrant's Bylaws. The amended Bylaws became effective May 23, 2006. The amended Bylaws provide that (i) the Chairman of the Board shall preside at any meeting of any of the Registrant's stockholders and (ii) the Audit and Corporate Governance Committee of the Board shall be comprised of at least two members, at least one of whom shall have been elected as a director by the holders of the Registrant's Class A Common Stock.

The preceding summary is not intended to be complete, and is qualified in its entirety by reference to the full text of the Amended and Restated Bylaws attached hereto as Exhibit 3.1 hereto and incorporated herein by reference.

Item 9.01. Financial Statement and Exhibits

c) Exhibits.

The following exhibit is filed as part of this Report:

 

Exhibit Number

Description

   

3.1

Amended and Restated Bylaws of Alpharma Inc., as amended May 23, 2006.

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

ALPHARMA INC.



 

By: /s/ Robert F. Wrobel

 

Robert F. Wrobel
Executive Vice President and
Chief Legal Officer

Date: May 25, 2006